Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cedars-Sinai Medical Center
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
AstraZeneca
Taiho Oncology, Inc.
Revolution Medicines, Inc.
Beth Israel Deaconess Medical Center
Seagen Inc.
Seagen Inc.
Actuate Therapeutics Inc.
University of Arizona
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
H. Lee Moffitt Cancer Center and Research Institute
NYU Langone Health
University Medical Centre Ljubljana
Washington University School of Medicine
City of Hope Medical Center
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
CHU de Quebec-Universite Laval
Washington University School of Medicine
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Astellas Pharma Inc
Tomsk National Research Medical Center of the Russian Academy of Sciences
Institute of Cancer Research, United Kingdom
M.D. Anderson Cancer Center
Hoffmann-La Roche
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of California, Davis
Erasca, Inc.
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Duke University
AstraZeneca
Alliance for Clinical Trials in Oncology